India Anti-hypertensive Drugs Market Size & Outlook

The anti-hypertensive drugs market in India is expected to reach a projected revenue of US$ 1,902.8 million by 2033. A compound annual growth rate of 5.5% is expected of India anti-hypertensive drugs market from 2025 to 2033.
Revenue, 2024 (US$M)
$1,175.6
Forecast, 2033 (US$M)
$1,902.8
CAGR, 2025 - 2033
5.5%
Report Coverage
India

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

India anti-hypertensive drugs market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

India anti-hypertensive drugs market highlights

  • The India anti-hypertensive drugs market generated a revenue of USD 1,175.6 million in 2024 and is expected to reach USD 1,902.8 million by 2033.
  • The India market is expected to grow at a CAGR of 5.5% from 2025 to 2033.
  • In terms of segment, angiotensin ii receptor blockers (arbs) was the largest revenue generating product in 2024.
  • Fixed-Dose Combinations (FDCs) is the most lucrative product segment registering the fastest growth during the forecast period.


Anti-hypertensive drugs market data book summary

Market revenue in 2024USD 1,175.6 million
Market revenue in 2033USD 1,902.8 million
Growth rate5.5% (CAGR from 2025 to 2033)
Largest segmentAngiotensin ii receptor blockers (arbs)
Fastest growing segmentFixed-Dose Combinations (FDCs)
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationACE Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), Direct Renin Inhibitor, Calcium Channel Blockers, Diuretics, Mineralocorticoid Receptor Antagonists (MRAs), Beta-Blockers, Alpha-1 Blockers, Central Alpha-2 Agonists, Direct Vasodilators, Fixed-Dose Combinations (FDCs)
Key market players worldwideSanofi SA, Boehringer Ingelheim Pharma, Novartis AG ADR, Johnson & Johnson, Daiichi Sankyo Co Ltd, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, Lupin, Sun Pharmaceutical Industries


Other key industry trends

  • In terms of revenue, India accounted for 4.7% of the global anti-hypertensive drugs market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China anti-hypertensive drugs market is projected to lead the regional market in terms of revenue in 2033.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,964.5 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Anti-hypertensive Drugs Market Companies

Name Profile # Employees HQ Website
Boehringer Ingelheim Pharma View profile 10001+ Dortmund, Nordrhein-Westfalen, Germany, Europe https://www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund
Daiichi Sankyo Co Ltd View profile 17435 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 https://www.daiichisankyo.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
Lupin View profile 10001+ Mumbai, Maharashtra, India, Asia https://www.lupin.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

India anti-hypertensive drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-hypertensive drugs market will help companies and investors design strategic landscapes.


Angiotensin ii receptor blockers (arbs) was the largest segment with a revenue share of 25.14% in 2024. Horizon Databook has segmented the India anti-hypertensive drugs market based on ace inhibitors (aceis), angiotensin ii receptor blockers (arbs), direct renin inhibitor, calcium channel blockers, diuretics, mineralocorticoid receptor antagonists (mras), beta-blockers, alpha-1 blockers, central alpha-2 agonists, direct vasodilators, fixed-dose combinations (fdcs) covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to India anti-hypertensive drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of India anti-hypertensive drugs market databook

  • Our clientele includes a mix of anti-hypertensive drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the India anti-hypertensive drugs market, including forecasts for subscribers. This country databook contains high-level insights into India anti-hypertensive drugs market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

India Product - Anti-hypertensive Drugs Market, 2024 - 2033 (US$M)

India Anti-hypertensive Drugs Market Share, 2024 & 2033 (US$M)

India Product - Anti-hypertensive Drugs Market, 2024 - 2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online